Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram for Mood and Cognition in Glioblastoma
NCT02623231Phase 3Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Dec 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of escitalopram in major depressive disorder (MDD), cognitive impairment, sponsored by Tel Aviv Sourasky Medical Center. Status: unknown.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)cognitive impairment
Beyond the preview
Go deeper on NCT02623231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623231.